Aeterna Zentaris snags $69M pact on perifosine

Canada's Aeterna Zentaris will pocket $8.3 million upfront from Yakult Honsha, which is licensing the Japanese rights to Aeterna's lead cancer drug, perifosine. Aeterna is also in line for up to $60.9 million in milestones. Perifosine is an oral PI3K/Akt inhibitor currently in two Phase III programs for the treatment of colorectal cancer and multiple myeloma in the United States and Europe. Aeterna release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.